NASDAQ:XBITXBiotech Stock Price, Forecast & News

XBiotech's stock was trading at $10.72 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, XBIT shares have increased by 33.3% and is now trading at $14.29. View which stocks have been most impacted by Coronavirus.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for XBiotech in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for XBiotech.

XBiotech is scheduled to release its next quarterly earnings announcement on Thursday, June 11th 2020. View our earnings forecast for XBiotech.

XBiotech Inc (NASDAQ:XBIT) announced its earnings results on Tuesday, November, 12th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.15). View XBiotech's earnings history.

2 equities research analysts have issued 12 month price targets for XBiotech's shares. Their forecasts range from $18.00 to $28.00. On average, they anticipate XBiotech's share price to reach $23.00 in the next twelve months. This suggests a possible upside of 61.0% from the stock's current price. View analysts' price targets for XBiotech.

Press coverage about XBIT stock has been trending positive this week, according to InfoTrie Sentiment. InfoTrie rates the sentiment of press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. XBiotech earned a media sentiment score of 2.4 on InfoTrie's scale. They also gave news stories about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the next few days. View the latest news aboutXBiotech.

XBiotech saw a decrease in short interest in May. As of May 15th, there was short interest totaling 2,220,000 shares, a decrease of 7.5% from the April 30th total of 2,400,000 shares. Based on an average daily volume of 513,200 shares, the short-interest ratio is currently 4.3 days. Approximately 16.2% of the company's shares are sold short. View XBiotech's Current Options Chain.

Some companies that are related to XBiotech include Ironwood Pharmaceuticals (IRWD), Opko Health (OPK), Constellation Pharmaceuticals (CNST), Akebia Therapeutics (AKBA), BELLUS Health (BLUSF), Dicerna Pharmaceuticals (DRNA), Akcea Therapeutics (AKCA), I-Mab (IMAB), CytoDyn (CYDY), ZEALAND PHARMA/S (ZEAL), Arcus Biosciences (RCUS), Innoviva (INVA), Amneal Pharmaceuticals (AMRX), Myovant Sciences (MYOV) and Portola Pharmaceuticals (PTLA). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other XBiotech investors own include Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Cidara Therapeutics (CDTX), Micron Technology (MU), Novavax (NVAX), Ocular Therapeutix (OCUL), Sanofi (SNY), Crispr Therapeutics (CRSP), SCYNEXIS (SCYX) and VBI Vaccines (VBIV).

(XBIT) raised $76 million in an initial public offering (IPO) on Wednesday, April 15th 2015. The company issued 4,000,000 shares at a price of $18.00-$20.00 per share. WR Hambrecht + Co served as the underwriter for the IPO.

XBiotech trades on the NASDAQ under the ticker symbol "XBIT."

XBiotech's stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (4.47%), Geode Capital Management LLC (0.96%), State Street Corp (0.92%), Jane Street Group LLC (0.49%), Russell Investments Group Ltd. (0.36%) and Nuveen Asset Management LLC (0.21%). Company insiders that own XBiotech stock include Fondation Rennes, Street Financial SA Bay, W Thorpe Mckenzie and W Thorpe Mckenzie. View institutional ownership trends for XBiotech.

XBIT stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., State Street Corp, Geode Capital Management LLC, Alps Advisors Inc., Squarepoint Ops LLC, Bank of New York Mellon Corp, Morgan Stanley, and Nuveen Asset Management LLC. View insider buying and selling activity for XBiotech.

XBIT stock was bought by a variety of institutional investors in the last quarter, including Jane Street Group LLC, Balyasny Asset Management LLC, Russell Investments Group Ltd., Paloma Partners Management Co, Alliancebernstein L.P., AQR Capital Management LLC, BNP Paribas Arbitrage SA, and Meeder Asset Management Inc.. Company insiders that have bought XBiotech stock in the last two years include Fondation Rennes, and W Thorpe Mckenzie. View insider buying and selling activity for XBiotech.

Shares of XBIT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of XBIT stock can currently be purchased for approximately $14.29.

XBiotech has a market capitalization of $412.27 million. XBiotech employs 56 workers across the globe.

The official website for XBiotech is www.xbiotech.com.

XBiotech's mailing address is 5217 Winnebago Ln, AUSTIN TX, 78744. The biopharmaceutical company can be reached via phone at 512-386-2900 or via email at [email protected]